Medical Advocates
Nevirapine (Viramune)

Perinatal/Neonate Safety/Resistance/
Viral Dynamics

Safety
Resistance
Viral Dynamics

Perinatal NVP Main Page

Main New/Newsworthy

Home Page

Last Update: January 03, 2009
Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

Safety

Journal Papers, Abstracts, and Commentaries

Safety of nevirapine in pregnancy.
Natarajan U, Pym A, McDonald C, et al
HIV Med. 2007 Jan;8(1):64-9
Abstract

Safety of nevirapine-containing antiretroviral triple therapy regimens to prevent vertical
transmission in an African cohort of HIV-1-infected pregnant women.
Marazzi MC, Germano P, Liotta G, Guidotti G, et
HIV Med. 2006 Jul;7(5):338-44.
Abstract

Safety and trough concentrations of nevirapine prophylaxis given daily, twice weekly,
or weekly in breast-feeding infants from birth to 6 months.
Shetty AK, Coovadia HM, Mirochnick MM, et al
J Acquir Immune Defic Syndr. 2003 Dec 15;34(5):482-90
Abstract

Conference Reports, Abstracts, and Posters

Maternal and fetal safety of nevirapine-containing HAART regimens during pregnancy
Coll O, Lonca M, Ocaña I, et al
(4th IAS Conference)
Abstract

Resistance

Journal Papers, Abstracts, and Commentaries

FULL-TEXT ARTICLE
Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine
prophylaxis in subtype C HIV-infected infants.
Moorthy A, Gupta A, Bhosale R, et al
PLoS ONE. 2009;4(1):e4096.
Paper

Prevalence of Nevirapine-Associated Resistance Mutations after Single Dose Prophylactic
Treatment among Antenatal Clinic Attendees in North Rift Kenya.
Kiptoo M, Ichimura H, Wembe RL, et al
AIDS Res Hum Retroviruses. 2008 Dec;24(12):1555-9.
Abstract

Analysis of Nevirapine (NVP) Resistance in Ugandan Infants Who Were HIV Infected Despite Receiving
Single-Dose (SD) NVP versus SD NVP Plus Daily NVP Up to 6 Weeks of Age to Prevent HIV Vertical
Transmission.
Church JD, Omer SB, Guay LA, et al
J Infect Dis. 2008 Aug 6.
Abstract

Nevirapine Resistance in Women and Infants after First versus Repeated Use of Single-Dose Nevirapine
for Prevention of HIV-1 Vertical Transmission.
Flys TS, McConnell MS, Matovu F, et al
J Infect Dis. 2008 Jun 26.
Abstract

Low rate of emergence of nevirapine and lamivudine resistance after post-partum interruption of a
triple-drug regimen.
Pérez H, Vignoles M, Laufer N
Abstract

Use of single-dose nevirapine for the prevention of mother-to-child transmission of HIV-1: does
development of resistance matter?
McConnell MS, Stringer JS, Kourtis AP, et al
Am J Obstet Gynecol. 2007 Sep;197(3 Suppl):S56-6
Abstract

Drug Resistance in Plasma and Breast Milk after Single-Dose Nevirapine in Subtype C
HIV Type 1: Population and Clonal Sequence Analysis.
Kassaye S, Lee E, Kantor R, et al
AIDS Res Hum Retroviruses. 2007 Aug;23(8):1055-61
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Prevalence of resistance to nevirapine in mothers and children after single-dose exposure
to prevent vertical transmission of HIV-1: a meta-analysis.
Arrive E, Newell ML, Ekouevi DK, et al
Int J Epidemiol. 2007 May 28;
Abstract

Persistence of K103N-Containing HIV-1 Variants after Single-Dose Nevirapine for
Prevention of HIV-1 Mother-to-Child Transmission.
Flys TS, Donnell D, Mwatha A, et al
J Infect Dis. 2007 Mar 1;195(5):711-5
Abstract

Response to Antiretroviral Therapy after a Single, Peripartum Dose of Nevirapine.
Lockman S, Shapiro RL, Smeaton LM, et al
N Engl J Med. 2007 Jan 11;356(2):135-147.
Abstract

Impact of NVP plasma concentration on selection of resistant virus in mothers who
received single dose NVP to prevent perinatal HIV-1 transmission and persistence of
resistant virus in their infected children.
Chaix ML, Ekouevi DK, Peytavin G, et al
Antimicrob Agents Chemother. 2006 Dec 18;
Abstract

Persistence of nevirapine-resistant HIV-1 in women after single-dose nevirapine therapy
for prevention of maternal-to-fetal HIV-1 transmission.
Palmer S, Boltz V, Martinson, et al
Proc Natl Acad Sci U S A. 2006 Apr 25;
Abstract

A WEEK-IN-REVIEW FEATURED REPORT
Transmission of Human Immunodeficiency Virus Type 1 Nevirapine Resistance Mutaton
K103Nfrom a Treatment-Naive Mother to her Child
Schmitz T, Kleinkauf N, Klempa B, et al
Pediatr Infect Dis J. 2006 Mar;25(3):275-276
Abstract

Low Risk of Nevirapine Resistance Mutations in the Prevention of Mother-to-Child Transmission
of HIV-1: Agence Nationale de Recherches sur le SIDA Ditrame Plus, Abidjan, Cote d'Ivoire.
Chaix ML, Ekouevi DK, Rouet F, et al
J Infect Dis. 2006 Feb 15;193(4):482-7.
Abstract

Development of Nevirapine Resistance in Infants Is Reduced by Use of Infant-Only
Single-Dose Nevirapine plus Zidovudine Postexposure Prophylaxis for the Prevention
of Mother-to-Child Transmission of HIV-1.
Eshleman SH, Hoover DR, Hudelson SE
J Infect Dis. 2006 Feb 15;193(4):479-81.
Abstract

Characterization of Nevirapine (NVP) Resistance Mutations and HIV Type 1 Subtype in
Women from Abidjan (Cote d'Ivoire) After NVP Single-Dose Prophylaxis of HIV Type 1
Mother-to-Child Transmission.
Toni TD, Masquelier B, Lazaro E, et al
AIDS Res Hum Retroviruses. 2005 Dec;21(12):1031-4.
Abstract

Distinct Patterns of Emergence and Fading of K103N and Y181C in Women With Subtype
A vs. D After Single-Dose Nevirapine: HIVNET 012.
Eshleman SH, Guay LA, Wang J, et al
J Acquir Immune Defic Syndr. 2005 Sep 1;40(1):24-29.
Abstract

Breast-Milk Shedding of Drug-Resistant HIV-1 Subtype C in Women Exposed to
Single-Dose Nevirapine.
Lee EJ, Kantor R, Zijenah L, et al
J Infect Dis. 2005 Oct 1;192(7):1260-4.

Emergence of Drug-Resistant HIV-1 after Intrapartum Administration of Single-Dose
Nevirapine Is Substantially Underestimated.
Johnson JA, Li JF, Morris L, et al
J Infect Dis. 2005 Jul 1;192(1):16-23.
Abstract

Sensitive Drug-Resistance Assays Reveal Long-Term Persistence of HIV-1 Variants with
the K103N Nevirapine (NVP) Resistance Mutation in Some Women and Infants after the
Administration of Single-Dose NVP: HIVNET 012.
Flys T, Nissley DV, Claasen CW,
J Infect Dis. 2005 Jul 1;192(1):24-9.
Abstract

Nevirapine (NVP) Resistance in Women with HIV-1 Subtype C, Compared with Subtypes
A and D, after the Administration of Single-Dose NVP.
Eshleman SH, Hoover DR, Chen S, et
J Infect Dis. 2005 Jul 1;192(1):30-6
Abstract

Persistence of Nevirapine Exposure During the Postpartum Period After Intrapartum Single-
Dose Nevirapine in Addition to Zidovudine Prophylaxis for the Prevention of Mother-to-Child
Transmission of HIV-1.
Cressey TR, Jourdain G, Lallemant MJ, et al
J Acquir Immune Defic Syndr. 2005 Mar 1;38(3):283-288.
Abstract

Characterization of Nevirapine Resistance Mutations in Women With Subtype A Vs.
D HIV-1 6-8 Weeks After Single-Dose Nevirapine (HIVNET 012).
Eshleman SH, Guay LA, Mwatha A, et al
J Acquir Immune Defic Syndr. 2004 Feb 1; 35(2): 126-130.
Abstract

Development of resistance mutations in women receiving standard antiretroviral therapy
who received intrapartum nevirapine to prevent perinatal human immunodeficiency virus
type 1 transmission: a substudy of pediatric AIDS clinical trials group protocol 316.
Cunningham CK, Chaix ML, Rekacewicz C, et al
J Infect Dis 2002 Jul 15;186(2):181-8
Abstract

Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to
prevent HIV-1 vertical transmission.
Jackson JB, Becker-Pergola G, Guay LA, et al
AIDS 2000 Jul 28;14(11):F111-5
Abstract

Pharmacological implications of lengthened in-utero exposure to nevirapine.
Taylor GP, Lyall EG, Back D, Ward C, Tudor-Williams G.
Lancet 2000 Jun 17;355(9221):2134-5
Abstract

Conference Reports, Abstracts, and Posters

Nevirapine metabolism and association with drug resistance in breast milk and plasma
S. Kassaye , E. Lee , D. Holland, et al
(XVII International AIDS Conference)
Abstract

Detection of minor drug-resistant populations in plasma of HIV-infected children and their mothers after
single-dose nevirapine
A. Kunz, A. Hauser, K. Mugenyi, et al
(XVII International AIDS Conference)
Abstract

Intrapartum Tenofovir and Emtricitabine Reduces Development of Low-level NNRTI Resistance
following Ingestion of Single-dose Nevirapine for Perinatal HIV Prevention
B Chi, L Frenkel, G Aldrovandi, et al
(15th CROI)
Abstract

The TEmAA ANRS 12109 Phase II Trial, Step 1: Tolerance and Viral Resistance after Single-dose
Nevirapine and Short-course of Tenofovir Disoproxil Fumarate and Emtricitabine to Prevent
Mother-to-Child Transmission of HIV-1
E Arrive, M Chaix E Nerriene, et al
(15th CROI)
Abstract

Emergence and Fading of Nevirapine Resistance after First versus Repeated Use of Single-dose
Nevirapine for Prevention of Mother-to-Child HIV Transmission: Women and Infants in the Repeat
Pregnancy Study in Uganda
S Eshleman T Flys, M McConnell
(15th CROI)
Abstract

Analysis of NVP Resistance in Ugandan Infants Who Were HIV-infected despite Receiving
Single-dose Nevirapine vs Single-dose NVP Plus up to 6 Weeks of Daily NVP to Prevent HIV
Vertical Transmission
J Church, S Omer, L Guay, et al
(15th CROI)
Abstract

Low emergence of nevirapine (NVP) and lamivudine (3TC) resistance after post-partum
interruption of a triple drug regimen for prevention of HIV mother to child transmission
(MTCT)
Pérez H, Vignoles M, Laufer N, et al
(4th IAS Conference)
Abstract

Development of phenotypic HIV-1 drug resistance following exposure to single dose nevirapine
Basson A, Ntsala M, Tlale E, et al
(4th IAS Conference)
Abstract

Detection of the onset of drug resistant mutations in pregnant women receiving single dose
nevirapine in Namakkal, Tamilnadu, using oligonucleotide ligation assay
Jacob SM, Durairaj A, Vijayakumari JJ, et al
(4th IAS Conference)
Abstract

Nevirapine-resistant HIV-1 among Mozambican Infants Infected in Utero vs Intra-partum
or Early Postpartum
M Micek, A Blanco, A Blanco, et al
(14 CROI)
Abstract

Clonal analysis of the diversity in drug resistant subtype C HIV-1 after single dose nevirapine
Kassaye S., Lee E., Johnston B., Kantor R., Katzenstein D.
(XVI International AIDS Conference)
Abstract

Resistance induced by the use of single dose nevirapine (sdNVP) for prevention of
mother-to-child transmission of HIV (PMTCT): debate and reality, experience in Nigeria
Mandala J., Abutu A., Anomnachi L
(XVI International AIDS Conference)
Abstract

POSTER
Analysis of K103N-containing HIV-1 Variants in Women with HIV-1 Subtypes A, C, and D
after Single-dose Nevirapine Using a Sensitive and Quantitative Point Mutation Assay
T S. Flys, S Chen, D Jones, et al
(13 CROI)
PDF Poster Abstract

Selection of Resistance Mutations in Children Receiving Prophylaxis with Lamivudine or
Nevirapine for the Prevention of Postnatal Transmission of HIV
M Giuliano, C Galluzzo, E Germinario, et al
(12 CROI)
Abstract

Clonal Analysis of Drug-resistant Mutations in Plasma and Breast Milk following
Single-dose Nevirapine
E Lee, R Kantor, E Johnston, et al
(12 CROI)
Abstract

Controversies in the Use of Nevirapine for Prevention of Mother-to-Child Transmission
J McIntyre
(12 CROI)
Abstract

Infant Zidovudine Prophylaxis and Emergence of Nevirapine Resistance at 6 Weeks in
Perinatally HIV-infected Infants Exposed to Intra-partum or Newborn Nevirapine
N Ngo-Giang-Huong, G Jourdain, P Tungyai, et al
(12 CROI)
Abstract

Sensitive Drug Resistance Assays Reveal Long-term Persistence of HIV-1 Variants with
the K103N Nevirapine-resistance Mutation in Some Women and Infants after Single-dose
NVP: HIVNET 012
S Eshleman, D Nissley, C Claasen, et al
(12 CROI)
Abstract

Nevirapine Resistance and Survival of Women Receiving HAART Subsequent to Prevention
of Mother-to-Child Transmission: A Population-based Stochastic Model
D Westreich , A Van Rie, F Behets, et al
(12 CROI)
Abstract

Persistence of NNRTI-r Resistant Variants after Single-dose Nevirapine in HIV-1 Subtype-
C-infected Women
S Palmer , V Boltz, F Maldarelli, et al
(12 CROI)
Abstract

Resistance Emerges in the Majority of Women Provided Intrapartum Single-dose Nevirapine
J Johnson, J F Li, L Morris, et al
(12 CROI)
Abstract

Nevirapine resistance mutations among HIV-1 infected infants following single dose nevirapine
CCN Pillay, G Gray, C Chezzi, et al
(15IAC)
Abstract

Resistance patterns in mother-infant pairs following single dose nevirapine (NVP) for the
prevention of mother-to-child transmission (MTCT) of HIV-1.
M Gordon, N Graham, R Bland, et al
(15IAC)
Abstract

Comparison of genotypic and phenotypic assays for measuring nevirapine resistance
among women participating in mother-to-child prevention programs
M Ntsala, C Pillay, E Tlale, et al
(15IAC)
Abstract

Persistence of nevirapine resistance mutations 6 months following single dose nevirapine
L Morris, N Martinson, C Pillay,et al
(15IAC)
Abstract

Profile of NNRI associated mutations in women exposed to a single dose of nevirapine
during delivery in Thailand
N Ngo-Giang-Huong, P Tungyai, A Kummee
(15IAC)
Abstract

Modeling the sexual transmission of HIV-1 strains resistant to nevirapine from MTCT programs
A Medley, K O'Reilly, G Schmid, M D Sweat
(15IAC)
Abstract

HIV-1 GENOTYPIC RESISTANCE TO ANTIRETROVIRAL TREATMENT IN CAMEROON,
IN POPULATIONS TREATED BY HAART AND BY SINGLE-DOSE NEVIRAPINE TO
PREVENT MTCT
C. Kouanfack, L. Vergne, M. Tardy, et al
(2nd IAS)
Abstract

POSTER
Nevirapine Plasma Concentrations Are Still Detectable after More than 2 Weeks in the
Majority of Women Receiving Single-dose NVP: Implications for Intervention Studies
E Muro, J Droste, H ter Hofstede, et al
(11 CROI
PDF Poster Abstract

POSTER
Rapid flux in non-nucleoside reverse transcriptase inhibitor resistance mutations among
subtype C HIV-1-infected women after single dose nevirapine
D Katzenstein, et al.
(XII International HIV Drug Resistance Workshop)
PDF Poster

POSTER
HIV-1 pol gene diversity and archived Nevirapine resistance mutation in pregnant women
in Rwanda
J Servais, C Lambert , E Karita, et al
(Ist Euro Conference)
PDF Poster

Selection of Nevirapine Resistance (NVPR) Mutations in Ugandan Women and Infants
Receiving NVP Prophylaxis To Prevent HIV-1 Vertical Transmission (HIVNET-012).
(8 CROI)
Abstract

Viral Dynamics

Journal Papers, Abstracts, and Commentaries

Nevirapine Plasma Concentrations are Still Detectable After More Than 2 Weeks in the Majority of
Women Receiving Single-Dose Nevirapine: Implications for Intervention Studies.
Muro E, Droste JA, Hofstede HT
J Acquir Immune Defic Syndr. 2005 Aug 1;39(4):419-421.
Abstract

FULL-TEXT ARTICLE
Intrapartum Exposure to Nevirapine and Subsequent Maternal Responses to Nevirapine-
Based Antiretroviral Therapy.
Jourdain G, Ngo-Giang-Huong N, Le Coeur S, et al
N Engl J Med. 2004 Jul 9
Abstract

Conference Reports, Abstracts, and Posters
	Receipt of single dose nevirapine in labor may defer rather than blunt the postpartum breast milk HIV viral load rebound seen after the discontinuation of ZDV Rossenkhan R, Ndung'u T, Sebunya TK, et al (4th IAS Conference) Abstract

Perinatal NVP Main Page

Main New/Newsworthy

Home Page

Nevirapine Perinatal/Neonate Data